Transferrin-Modified Doxorubicin-Loaded Biodegradable Nanoparticles Exhibit Enhanced Efficacy in Treating Brain Glioma-Bearing Rats
Authors:
- 1 November 2013
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 28 (9) , 691-696
Abstract
Doxorubicin (Dox) is widely used for the treatment of solid tumors but its clinical utility on glioma is limited. In this study, we developed a novel nano-scale drug delivery system employing biodegradable nanoparticle (NP) as carriers to load Dox. Transferrin (Tf) was conjugated to the surface of NP to specifically target the NP to glioma. Tf-NP-Dox was prepared via emulsification-solvent evaporation method, and characterized for the size, Drug loading capacity (DLC), entrapment efficiency, and Tf number on the surface. The antitumor efficiency in vitro was evaluated via CCK-8 assay. The transmembrane transportation was evaluated via HPLC assay. The antitumor efficiency in vivo was assessed in C6 glioma intracranial implant rat model. The average diameter of Tf-NP-Dox was 100 nm with ∼32 Tf molecules on the surface. DLC was 4.4%. CCK-8 assay demonstrated much stronger cytotoxicity of Tf-NP-Dox to C6 glioma cells compared to NP-Dox or Dox. HPLC assay showed that Tf-NP-Dox transported Dox into C6 cells with high efficiency. In vivo , Tf-NP-Dox could transport Dox into tumors compare to contralateral part, with tumor inhibitory ratio and survival higher than NP-Dox or Dox. Taken together, our results suggest that Tf-NP-Dox exhibits better therapeutic effects against glioma both in vitro and in vivo , and is a potential nano-scale drug delivery system for glioma chemotherapy.Keywords
This publication has 22 references indexed in Scilit:
- Imaging, Autoradiography, and Biodistribution of 188 Re-Labeled PEGylated Nanoliposome in Orthotopic Glioma Bearing Rat ModelCancer Biotherapy and Radiopharmaceuticals, 2011
- Inhibition of brain tumor growth by intravenous poly(β- l -malic acid) nanobioconjugate with pH-dependent drug releaseProceedings of the National Academy of Sciences, 2010
- Nanotechnology Platforms in Diagnosis and Treatment of Primary Brain TumorsRecent Patents on Nanotechnology, 2010
- Transferrin Receptor 2 Is Frequently and Highly Expressed in GlioblastomasTranslational Oncology, 2010
- Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphateBiomaterials, 2007
- The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cellsClinical Immunology, 2006
- Lectin-conjugated PEG–PLA nanoparticles: Preparation and brain delivery after intranasal administrationBiomaterials, 2006
- Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain deliveryJournal of Controlled Release, 2005
- Primary brain tumours in adultsThe Lancet, 2003
- Synthesis of Pegylated ImmunonanoparticlesPharmaceutical Research, 2002